Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.

Sofroniadou S, Goldsmith D.

Drug Saf. 2011 Feb 1;34(2):97-115. doi: 10.2165/11585040-000000000-00000.

PMID:
21247219
2.

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Teachey DT, Grupp SA, Brown VI.

Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. Review.

3.

Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology.

Fogel AL, Hill S, Teng JM.

J Am Acad Dermatol. 2015 May;72(5):879-89. doi: 10.1016/j.jaad.2015.01.014. Epub 2015 Mar 11. Review.

PMID:
25769191
4.

Placental, lipid, and glucidic effects of mammalian target of rapamycin inhibitors: impact on fetal growth and metabolic disorders during pregnancy after solid organ transplantation.

Framarino-dei-Malatesta M, Derme M, Napoli A, Iaria G, Manzia TM, Orlando G, Casorelli A, Berloco P.

Transplant Proc. 2014 Sep;46(7):2254-8. doi: 10.1016/j.transproceed.2014.07.047. Review.

PMID:
25242764
5.

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.

Khokhar NZ, Altman JK, Platanias LC.

Curr Opin Oncol. 2011 Nov;23(6):578-86. doi: 10.1097/CCO.0b013e32834b892d. Review.

PMID:
21892085
6.

Adverse events associated with mTOR inhibitors.

Pallet N, Legendre C.

Expert Opin Drug Saf. 2013 Mar;12(2):177-86. doi: 10.1517/14740338.2013.752814. Epub 2012 Dec 20. Review.

PMID:
23252795
7.

mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.

Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J.

Int J Cancer. 2016 May 15;138(10):2312-21. doi: 10.1002/ijc.29887. Epub 2015 Oct 27. Review.

8.

Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.

Xu J, Tian D.

Curr Med Res Opin. 2014 Jan;30(1):67-74. doi: 10.1185/03007995.2013.844116. Epub 2013 Oct 4. Review.

PMID:
24028709
9.

mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

Grzybowska-Izydorczyk O, Smolewski P.

Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Review.

PMID:
22416776
10.

Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.

Mohindra NA, Platanias LC.

Leuk Lymphoma. 2015;56(9):2518-23. doi: 10.3109/10428194.2015.1026816. Epub 2015 May 12.

PMID:
25747970
11.

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

Sankhala K, Giles FJ.

Expert Rev Hematol. 2009 Aug;2(4):399-414. doi: 10.1586/ehm.09.31.

PMID:
21082945
12.

Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use.

Touzot M, Soulillou JP, Dantal J.

Curr Opin Organ Transplant. 2012 Dec;17(6):626-33. doi: 10.1097/MOT.0b013e32835a4be2. Review.

PMID:
23080066
13.

[Use of mTOR-inhibitors in solid tumors].

Seidel C, Grünwald V.

Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Review. German.

PMID:
21528529
14.

[Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].

Caletti C, Granata S, Tomei P, Lupo A, Zaza G.

G Ital Nefrol. 2014 Jul-Aug;31(4). pii: gin/31.4.2. Review. Italian.

PMID:
25098457
15.

Mammalian target of rapamycin as a target in hematological malignancies.

Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS.

Target Oncol. 2011 Mar;6(1):53-61. doi: 10.1007/s11523-011-0175-8. Epub 2011 Apr 17. Review.

PMID:
21499765
16.

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.

Kahan B.

Expert Opin Drug Saf. 2011 Sep;10(5):727-49. doi: 10.1517/14740338.2011.579898. Epub 2011 May 11. Review.

PMID:
21557712
17.

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.

Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.

18.

Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?

Bhat M, Watt KD.

Clin Transplant. 2015 Jul;29(7):654-63. doi: 10.1111/ctr.12559. Epub 2015 Jun 10. Review.

PMID:
26094583
19.

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.

Transplant Proc. 2010 Oct;42(8):3050-2. doi: 10.1016/j.transproceed.2010.07.083.

PMID:
20970607
20.

The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.

Klintmalm GB, Saab S, Hong JC, Nashan B.

Clin Transplant. 2014 Jun;28(6):635-48. doi: 10.1111/ctr.12357. Epub 2014 Apr 21. Review.

PMID:
24628264

Supplemental Content

Support Center